Publications by authors named "Simona Barbato"

Claim this Profile
C
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma.
Marco Talarico, Gisella Vischini, Simona Barbato, Roberta Restuccia, Simone Masci

Front Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. 2025, , 1168.
Katia Mancuso, Simona Barbato, Francesco Di Raimondo, Francesca Gay, Pellegrino Musto

Cancers (Basel)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home.
Flavia Bigi, Mauro Fiacchini, Roberta Restuccia, Simone Masci, Gaia Mazzocchetti, Simona Barbato

Clin Exp Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.
Katia Mancuso, Marco Talarico, Enrica Manzato, Simona Barbato, Paola Tacchetti

Cancers (Basel)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma.
Katia Mancuso, Simona Barbato, Francesco Di Raimondo, Francesca Gay, Pellegrino Musto

Cancers (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma.
Katia Mancuso, Simona Barbato, Marco Talarico, Paola Tacchetti, Elena Zamagni

Expert Opin Biol Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Challenges in Bladder Cancer Diagnosis: How Biosensing Tools Can Lead to Population Screening Opportunities.
Fabiana Tortora, Antonella Guastaferro, Simona Barbato, Ferdinando Febbraio, Amelia Cimmino

Sensors (Basel)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Lorella Salce, Simona Barbato, Francesco Bianchini, Daniela Renna

Recenti Prog Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients-A Systematic Review.
Flavia Bigi, Enrica Manzato, Simona Barbato, Marco Talarico, Michele Puppi

Pharmaceuticals (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
Paola Tacchetti, Marco Talarico, Simona Barbato, Lucia Pantani, Katia Mancuso

Expert Rev Anticancer Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma.
Paola Tacchetti, Simona Barbato, Katia Mancuso, Elena Zamagni, Michele Cavo

Cancers (Basel)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
Elena Zamagni, Stefania Oliva, Francesca Gay, Andrea Capra, Delia Rota-Scalabrini, Simona Barbato

EClinicalMedicine· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma.
Katia Mancuso, Elena Zamagni, Vincenza Solli, Liliana Gabrielli, Marta Leone, Simona Barbato

Front Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.
Paola Tacchetti, Serena Rocchi, Elena Zamagni, Simona Barbato, Ilaria Rizzello

Am J Hematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How I treat high-risk multiple myeloma.
Elena Zamagni, Simona Barbato, Michele Cavo

Blood· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients.
Paola Tacchetti, Serena Rocchi, Simona Barbato, Elena Zamagni, Lucia Pantani

Expert Rev Hematol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study.
Ilaria Rizzello, Michele Cavo, Luca Dozza, Elena Rivolti, Maria Teresa Petrucci, Simona Barbato

Leuk Lymphoma· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardization of F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma.
Elena Zamagni, Cristina Nanni, Luca Dozza, Thomas Carlier, Clément Bailly, Simona Barbato

J Clin Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Paola Tacchetti, Lucia Pantani, Francesca Patriarca, Maria Teresa Petrucci, Elena Zamagni, Simona Barbato

Lancet Haematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients.
Elena Zamagni, Paola Tacchetti, Simona Barbato, Michele Cavo

J Clin Med· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRNAs in Oncogenesis and Tumor Suppression.
Simona Barbato, Giancarlo Solaini, Muller Fabbri

Int Rev Cell Mol Biol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First Italian Ebola virus disease case: management of hospital internal and external communication.
Lorella Salce, Simona Barbato, Daniela Renna, Francesco Bianchini, Paola Vaccaro

New Microbiol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The inhibitor protein (IF1) of the F1F0-ATPase modulates human osteosarcoma cell bioenergetics.
Simona Barbato, Gianluca Sgarbi, Giulia Gorini, Alessandra Baracca, Giancarlo Solaini

J Biol Chem· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis